Results 91 to 100 of about 433 (169)

Loss of tumor-infiltrating lymphocytes and poor response to immunotherapy in IDH GOF mutant melanoma. [PDF]

open access: yesJCI Insight
Specht E   +11 more
europepmc   +1 more source

IL10R Inhibition Induces Neutrophil Tumoricidal Activity. [PDF]

open access: yesCancer Immunol Res
Khalil DN   +36 more
europepmc   +1 more source

1067 Safety and efficacy of ANK-302, an alum anchored CD28 and IL-2 bi-agonist in preclinical tumor models

open access: yesJournal for ImmunoTherapy of Cancer
Kanika Jain   +4 more
doaj   +1 more source

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial. [PDF]

open access: yesJ Clin Oncol
Srour SA   +15 more
europepmc   +1 more source

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer. [PDF]

open access: yesClin Cancer Res
Cowzer D   +26 more
europepmc   +1 more source

Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study. [PDF]

open access: yesJ Clin Oncol
Medina T   +19 more
europepmc   +1 more source

Ankyra

open access: yes, 2012
Mihail Zahariade
core   +1 more source

930 Alum-anchored CD40–IL-2 multi-agonist (ANK-301) promotes local and abscopal anti-tumor immunity without systemic toxicity

open access: yesJournal for ImmunoTherapy of Cancer
Taha Merghoub   +7 more
doaj   +1 more source

iNOS is a key mediator of anti-PD-1 melanoma therapy response. [PDF]

open access: yesFront Immunol
Nguyen QT   +15 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy